share_log

Head to Head Survey: Advanced Biomedical Technologies (OTCMKTS:ABMT) Versus Vicarious Surgical (NYSE:RBOT)

Defense World ·  Dec 17, 2022 01:31

Vicarious Surgical (NYSE:RBOT – Get Rating) and Advanced Biomedical Technologies (OTCMKTS:ABMT – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares Vicarious Surgical and Advanced Biomedical Technologies' net margins, return on equity and return on assets.

Get Vicarious Surgical alerts:
Net Margins Return on Equity Return on Assets
Vicarious Surgical N/A -68.56% -45.62%
Advanced Biomedical Technologies N/A N/A N/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Vicarious Surgical and Advanced Biomedical Technologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vicarious Surgical 0 1 2 0 2.67
Advanced Biomedical Technologies 0 0 0 0 N/A
Vicarious Surgical presently has a consensus target price of $9.33, indicating a potential upside of 396.45%. Given Vicarious Surgical's higher possible upside, equities analysts clearly believe Vicarious Surgical is more favorable than Advanced Biomedical Technologies.

Volatility and Risk

Vicarious Surgical has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Advanced Biomedical Technologies has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Valuation & Earnings

This table compares Vicarious Surgical and Advanced Biomedical Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vicarious Surgical N/A N/A -$35.21 million $0.71 2.65
Advanced Biomedical Technologies $120,000.00 29.54 -$670,000.00 N/A N/A

Advanced Biomedical Technologies has higher revenue and earnings than Vicarious Surgical.

Insider & Institutional Ownership

51.8% of Vicarious Surgical shares are held by institutional investors. 52.5% of Vicarious Surgical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Vicarious Surgical beats Advanced Biomedical Technologies on 5 of the 9 factors compared between the two stocks.

About Vicarious Surgical

(Get Rating)

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

About Advanced Biomedical Technologies

(Get Rating)

Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.

Receive News & Ratings for Vicarious Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicarious Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment